StockNews.AI
LTRN
StockNews.AI
13 days

Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial

1. FDA cleared Starlight's IND application for Phase Ib/2a trial on STAR-001. 2. Trial targets glioblastoma patients, enhancing LTRN's development pipeline.

2m saved
Insight
Article

FAQ

Why Bullish?

FDA clearance enhances LTRN's credibility and potential revenue from advanced therapies, similar to past successes in drug approvals leading to price surges.

How important is it?

FDA clearance is critical; it directly facilitates LTRN's advancement in the competitive biotech sector, greatly enhancing investor confidence.

Why Long Term?

Successful trials can lead to market entry, potentially increasing LTRN's valuation and long-term growth, as seen in other biotech firms post-trial advancements.

Related Companies

GBMSPYXBI
DALLAS--(BUSINESS WIRE)--Starlight Therapeutics, a wholly owned subsidiary of Lantern Pharma Inc. (NASDAQ: LTRN), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase Ib/2a clinical trial to evaluate STAR-001 (LP-184) in combination with spironolactone for patients with glioblastoma multiforme (GBM) at first progression. The planned Phase Ib/2a clinical trial (IND 178511) is designed to investigate the safety, to.

Related News